Merck & Co, INC Form 4 insider transactions

Director Kathy J. Warden reports a transaction involving Merck & Co. common stock and phantom stock units.

Director Paul Rothman reports acquiring phantom stock units convertible to common stock in Merck & Co., Inc.

Director Inge G. Thulin reports acquisition of phantom stock units convertible to cash based on Merck's common stock value.

Director Douglas M. Baker Jr. reports a transaction involving phantom stock units of Merck & Co., to be settled in cash upon termination of service.

Mary Ellen Coe, a director of Merck & Co., Inc., reported the acquisition of phantom stock units settled in cash, according to a recent SEC Form 4 filing.

Pamela J. Craig, a director at Merck & Co., Inc., reported a transaction involving phantom stock units settled in cash, along with adjustments to common stock holdings due to dividend reinvestment.

Thomas Glocer, a director at Merck & Co., Inc., reported the acquisition of phantom stock units settled in cash, according to a recent SEC Form 4 filing.

Director Stephen Mayo reports acquiring phantom stock units and common stock through dividend reinvestment.

Director Risa Lavizzo-Mourey reports a transaction involving Merck & Co., Inc. common stock and phantom stock units.

Dalton Smart, SVP Fin. Global Controller at Merck & Co., Inc., reported multiple transactions involving common stock and restricted stock units on May 3rd and 4th, 2024.

Richard R. DeLuca Jr., an Executive Vice President at Merck & Co., Inc., reported the vesting and distribution of restricted stock units and associated tax withholding.

EVP and Chief Strategy Officer of Merck, Michael Klobuchar, reports the vesting and distribution of restricted stock units and related transactions.

Johannes Oosthuizen, a Merck executive, reported the vesting and distribution of restricted stock units and associated tax withholding.

Joseph Romanelli, President of Human Health International at Merck & Co., Inc., reports the acquisition and disposal of common stock and derivative securities.

EVP and Chief HR Officer of Merck & Co., Betty Larson, reports the acquisition of stock options and restricted stock units.

Dalton Smart, SVP Fin. Global Controller at Merck & Co., Inc., reported the acquisition and disposal of common stock and derivative securities.

Chief Marketing Officer of Merck & Co., Chirfi Guindo, reports acquisition of stock options and holdings in common stock and a 401(k) plan.

Cristal N. Downing, Chief Communications & Public Affairs Officer at Merck & Co., Inc., reported the acquisition of stock options on April 30, 2024.

EVP and General Counsel of Merck & Co., Jennifer Zachary, reports acquisition of stock options and holdings of common stock.

Executive VP & President, MRL, Dean Y. Li, reports acquisition of Merck stock options.

Johannes Oosthuizen, President, U.S. Market at Merck & Co., Inc., reports the acquisition of stock options and shares through dividend reinvestment.

Merck's CEO, Robert M. Davis, reports the acquisition of stock options and updates to his beneficial ownership of company stock.

Sanat Chattopadhyay, an Executive Vice President at Merck & Co., Inc., reported the acquisition of stock options and adjustments to his beneficial ownership of company stock through grantor retained annuity trusts.

David Michael Williams, EVP, Chief Information & Digital Officer at Merck & Co., Inc., acquired stock options and reported changes in beneficial ownership.

EVP and Chief Strategy Officer of Merck, Michael Klobuchar, reports acquisition of stock options and changes in beneficial ownership of common stock.

Caroline Litchfield, EVP & CFO of Merck & Co., Inc., reports the acquisition of stock options.

Richard R. DeLuca, EVP & President of Merck Animal Health, reports acquisition of restricted stock units and stock options, along with adjustments in common stock holdings through dividend reinvestments and 401(k) plan activity.

Director Peter C. Wendell reports acquisition of phantom stock units and disposition of common stock in Merck & Co., Inc.

Christine E. Seidman, a director at Merck & Co., Inc., acquired phantom stock units on March 28, 2024, according to a Form 4 filing with the SEC.

Director Thomas H. Glocer reports acquisition of phantom stock units and holdings in Merck & Co., Inc.